Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

Inclusion Criteria: * Males with active AGA on the vertex area of the scalp consistent with Norwood-Hamilton Grades of IIIv through V, excluding IIIa, IVa, and Va grades. * Willing to maintain the same hair style, approximate length, and hair colour throughout the duration of the study as documented in the global photograph at Day -2 of baseline. * Willing to have target areas shaved and to have temporary dot tattoos placed on their scalp. * Willing to comply with the study instructions and return to the site for required visits. * Must be willing and able to communicate and participate in the entire study and willing to use an electronic diary to record investigational product dosing. * Must provide written informed consent. Exclusion Criteria: * Participants with other type of alopecia other than AGA or any other concomitant skin or systemic disorder involving the scalp area. * Participants with sensitive, irritated, or abraded scalp area. * Participants who have undergone hair transplants or have had scalp reductions. * Concurrent treatments or interventions that could affect interpretation of study data, prior to or during the study, as specified in the protocol * Current evidence of another ongoing or acute relevant cutaneous infection, active systemic infection, or other significant skin conditions. * History of relevant sensitivity to any of the study products, or components thereof, or a history of drug or other allergy that contraindicates study participation. * Known allergy or sensitivity to tattoo ink. * Participant with relevant active or prior history of malignancies. * Participants with relevant cardiovascular disease including ischemic heart disease, cardiac arrhythmias, or congestive heart disease. * History of any relevant alcoholism, substance or drug abuse-related disorders in the past year or a positive toxicology screening panel, or alcohol breath test at Screening. * Clinically significant abnormal biochemistry, haematology or urinalysis values. * Any other relevant serious illness or medical, physical, or psychiatric condition(s) that, could interfere with full participation in the study, pose a significant risk to the participant; or interfere with interpretation of study data.